Answers are grounded in this paper and cite their sources.
Hematologic malignancies (HMs) pose a serious threat to human health and are associated with a high metastatic rate and poor prognosis. The strong tumor heterogeneity, marked therapeutic resistance, poor targeting of conventional therapies, and toxic side effects make them a major challenge in the clinical treatment of HMs. As the principal site of hematopoiesis and immune cell production, the bone marrow (BM) is a critical site in the treatment of HMs. However, low blood perfusion and the complexity of the microenvironment severely hinder drug accumulation within the BM, which is also the core bottleneck in the treatment of HMs. Owing to their unique physicochemical properties, nano-delivery systems enable efficient BM-targeted delivery, providing effective strategies to overcome this therapeutic bottleneck. This review discusses the structure of the BM and the mechanisms of delivery barriers, systematically analyzes the design advances of BM-targeted nano-delivery systems, highlights different delivery strategies, and addresses key issues in the clinical translation of nano-delivery systems, including biosafety, manufacturing, and regulation of in vivo delivery efficiency. It also outlines future directions, establishing a BM-targeted delivery framework to advance the treatment of HMs and providing a theoretical reference for the development and clinical application of BM-targeted nano-delivery systems, thereby facilitating breakthroughs in precision therapy for HMs.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: